Skip to main content
Figure 2 | Critical Care

Figure 2

From: Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment

Figure 2

Presepsin (left column) and IL-6 levels (right column) were significantly increased ( P <0.001) in non-survivors compared to survivors after 30 days (top) and 6 months (bottom) consistently at days 1, 3 and 8 of ICU treatment. IL-6 levels decreased both in survivors and non-survivors during the first week of ICU treatment (survivors: after 30 days, n = 58; 6 months, n = 44; non-survivors: after 30 days, n = 58; 6 months, n = 72; P = 0.001). A significant decrease of presepsin levels over days 1, 3 and 8 of ICU treatment was not detected (P = 0.59 and P = 0.39). Log-transformed biomarker concentrations were analyzed by two-way analysis of variance (ANOVA) to estimate the effects of the two factors, time and survival on biomarker levels. An interaction of survival with time was not detected. Data are presented as medians with 25th and 75th percentiles (boxes), smallest and largest values without extreme values (whiskers) and extreme values (points).

Back to article page